Patent
Promoterless cassettes for expression of alphavirus structural proteins
| العنوان: | Promoterless cassettes for expression of alphavirus structural proteins |
|---|---|
| Patent Number: | 7,850,977 |
| تاريخ النشر: | December 14, 2010 |
| Appl. No: | 12/143320 |
| Application Filed: | June 20, 2008 |
| مستخلص: | The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5′ replication recognition sequence, wherein at least one initiation codon has been removed from the 5′ replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3′ replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5′ and 3′ replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus nonstructural proteins. |
| Inventors: | Kamrud, Kurt I. (Apex, NC, US); Smith, Jonathan F. (Cary, NC, US); Maughan, Maureen (Durham, NC, US) |
| Assignees: | Alphavax, Inc. (Research Triangle Park, NC, US) |
| Claim: | 1. An isolated RNA molecule comprising: a) an alphavirus 5′ replication recognition sequence, wherein at least one initiation codon has been removed from the 5′ replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3′ replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5′ and 3′ replication recognition sequences of (a) and (c) direct replication of the entire RNA molecule in the presence of alphavirus nonstructural proteins. |
| Claim: | 2. The RNA molecule of claim 1 , wherein the nucleotide sequence encoding the alphavirus structural protein is selected from the group consisting of a nucleotide sequence encoding 1) an alphavirus capsid protein, 2) alphavirus E1 and E2 proteins in any order, 3) alphavirus capsid protein and alphavirus E1 protein in any order, 5) alphavirus capsid protein and alphavirus E2 protein in any order, 6) alphavirus E2 protein, and 7) alphavirus E1 protein. |
| Claim: | 3. The RNA molecule of claim 1 , wherein the alphavirus 5′ replication recognition sequence is the 5′ replication recognition sequence of Venezuelan equine encephalitis virus. |
| Claim: | 4. The RNA molecule of claim 3 , wherein the 5′ replication recognition sequence is between 70 and 524 nucleotides in length. |
| Claim: | 5. The RNA molecule of claim 1 , wherein the alphavirus 3′ replication recognition sequence is the 3′ replication recognition sequence of Venezuelan equine encephalitis virus. |
| Claim: | 6. The RNA molecule of claim 3 , wherein the alphavirus 3′ replication recognition sequence is the 3′ replication recognition sequence of Venezuelan equine encephalitis virus. |
| Claim: | 7. The RNA molecule of claim 1 , wherein the 3′ replication recognition sequence is 19 to 325 nucleotides in length. |
| Claim: | 8. The RNA molecule of claim 1 , wherein the at least one initiation codon is the initiation codon for nonstructural protein 1 (nsp1). |
| Claim: | 9. The RNA molecule of claim 1 , wherein all initiation codons have been removed from the 5′ replication recognition sequence. |
| Claim: | 10. The RNA molecule of claim 1 , wherein the RNA is capped at the 5′ terminus. |
| Claim: | 11. A population of alphavirus replicon particles, comprising a subset of particles comprising the RNA molecule of claim 1 , wherein the population contains no detectable replication-competent alphavirus virus particles per 10 8 alphavirus replicon particles, as determined by passage on permissive cells in culture. |
| Claim: | 12. A population of alphavirus replicon particles, comprising a subset of particles comprising the RNA molecule of claim 1 , wherein the population contains no detectable replication-competent alphavirus particles per 10 8 alphavirus replicon particles, as determined by passage on permissive cells in culture, wherein the alphavirus replicon particles comprise one or more attenuating mutations in either an alphavirus structural protein or an alphavirus nonstructural protein or both an alphavirus structural protein and an alphavirus nonstructural protein. |
| Claim: | 13. A composition comprising the population of claim 11 in a pharmaceutically acceptable carrier. |
| Claim: | 14. A composition comprising the population of claim 12 in a pharmaceutically acceptable carrier. |
| Claim: | 15. A method of inducing an immune response in a subject, comprising administering an effective amount of the population of claim 11 to the subject. |
| Claim: | 16. A method of inducing an immune response in a subject, comprising administering an effective amount of the population of claim 12 to the subject. |
| Claim: | 17. An isolated cell comprising the RNA molecule of claim 1 . |
| Claim: | 18. A vector comprising the RNA molecule of claim 1 . |
| Claim: | 19. A nucleic acid construct comprising the RNA molecule of claim 1 . |
| Claim: | 20. An isolated cell comprising the vector of claim 18 . |
| Claim: | 21. An isolated cell comprising the nucleic acid construct of claim 19 . |
| Current U.S. Class: | 4241/991 |
| Patent References Cited: | 4650764 March 1987 Temin et al. 4708871 November 1987 Geysen 5091309 February 1992 Schlesinger et al. 5185440 February 1993 Davis et al. 5217879 June 1993 Huang et al. 5505947 April 1996 Johnston et al. 5521082 May 1996 Lewis et al. 5639650 June 1997 Johnston et al. 5643576 July 1997 Johnston et al. 5703057 December 1997 Johnston et al. 5726022 March 1998 Burmer 5739026 April 1998 Garoff et al. 5766602 June 1998 Xiong et al. 5789245 August 1998 Dubensky, Jr. et al. 5792462 August 1998 Johnston et al. 5811407 September 1998 Johnston et al. 5814482 September 1998 Dubensky, Jr. et al. 5827658 October 1998 Liang et al. 5831016 November 1998 Wang et al. 5843723 December 1998 Dubensky, Jr. et al. 5853719 December 1998 Nair et al. 5958738 September 1999 Lindemann et al. 5989553 November 1999 Johnston et al. 6008035 December 1999 Johnston et al. 6015686 January 2000 Dubensky, Jr. et al. 6015694 January 2000 Dubensky, Jr. et al. 6146874 November 2000 Zolotukhin et al. 6156558 December 2000 Johnston et al. 6190666 February 2001 Garoff et al. 6194191 February 2001 Zhang et al. 6197502 March 2001 Renner et al. 6224879 May 2001 Sjöberg et al. 6242259 June 2001 Polo et al. 6261570 July 2001 Parker et al. 6267967 July 2001 Johnston et al. 6306388 October 2001 Nair et al. 6329201 December 2001 Polo et al. 6342226 January 2002 Betbeder et al. 6342372 January 2002 Dubensky, Jr. et al. 6376236 April 2002 Dubensky, Jr. et al. 6391632 May 2002 Dubensky, Jr. et al. 6426196 July 2002 Dubensky, Jr. et al. 6448389 September 2002 Gonczol et al. 6485958 November 2002 Blanche et al. 6495143 December 2002 Lee et al. 6521235 February 2003 Johnston et al. 6531135 March 2003 Johnston et al. 6541010 April 2003 Johnston et al. 6583121 June 2003 Johnston et al. 6767699 July 2004 Polo et al. 6770283 August 2004 Garoff et al. 6783939 August 2004 Olmsted et al. 6844188 January 2005 MacDonald et al. 6982087 January 2006 Johnston et al. 7045335 May 2006 Smith et al. 7078218 July 2006 Smith et al. 7235235 June 2007 Johnston et al. 7267823 September 2007 Hart et al. 7419674 September 2008 Chulay et al. 7425337 September 2008 Smith et al. 7442381 October 2008 Smith et al. 2001/0016199 August 2001 Johnston et al. 2002/0018766 February 2002 Roberts et al. 2002/0034521 March 2002 Lee et al. 2002/0102273 August 2002 Grieve et al. 2002/0141975 October 2002 Olmsted et al. 2002/0156251 October 2002 Prieur et al. 2002/0164582 November 2002 Hart et al. 2003/0021766 January 2003 Vajdy et al. 2003/0091591 May 2003 Xiong et al. 2003/0096397 May 2003 Schlesinger et al. 2003/0119182 June 2003 Smith et al. 2003/0120060 June 2003 Gonczol et al. 2003/0148262 August 2003 Polo et al. 2003/0152590 August 2003 Hevey et al. 2003/0232036 December 2003 Johnston et al. 2003/0232324 December 2003 Polo et al. 2004/0008458 January 2004 Kase et al. 2004/0009183 January 2004 Lee et al. 2004/0009945 January 2004 Lee et al. 2004/0029279 February 2004 Kovacs et al. 2004/0030117 February 2004 Johnston et al. 2004/0055037 March 2004 Gleba et al. 2004/0088764 May 2004 Gleba et al. 2004/0121466 June 2004 Johnston et al. 2004/0146859 July 2004 Hart et al. 2004/0166573 August 2004 Smith et al. 2004/0208848 October 2004 Smith et al. 2004/0255347 December 2004 Klimyuk et al. 2005/0014150 January 2005 Atabekov et al. 2005/0031592 February 2005 Doolan et al. 2005/0054107 March 2005 Chulay et al. 2005/0059004 March 2005 Atabekov et al. 2005/0118251 June 2005 Nagata et al. 2005/0123555 June 2005 Olmsted et al. 2005/0208020 September 2005 Doolan et al. 2005/0266550 December 2005 Rayner et al. 2006/0099587 May 2006 Johnston et al. 2006/0177819 August 2006 Smith et al. 2007/0065412 March 2007 Chen et al. 2007/0166820 July 2007 Smith et al. 2008/0213309 September 2008 Smith et al. 2008/0260775 October 2008 Johnston et al. 2008/0279891 November 2008 Johnston et al. 2009/0022760 January 2009 Smith et al. WO 92/10578 June 1992 WO 95/07994 March 1995 WO 95/27044 October 1995 WO 95/31565 November 1995 WO 96/17072 June 1996 WO 96/37220 November 1996 WO 96/37616 November 1996 WO 99/07834 February 1999 WO 99/08706 February 1999 WO 99/51263 October 1999 WO 00/39302 July 2000 WO 00/39318 July 2000 WO 00/61772 October 2000 WO 01/16343 March 2001 WO 02/03917 January 2002 WO 02/04493 January 2002 WO 02/10578 February 2002 WO 02/20721 March 2002 WO 03/023026 March 2003 WO 03/083065 October 2003 WO 2004/055166 July 2004 WO 2004/055167 July 2004 WO 2004/085660 October 2004 WO 2005/007689 January 2005 WO 2006085983 August 2006 |
| Other References: | Kamrud et al (Virology 360:376-387, 2007, available online Dec. 6, 2006). cited by examiner International Search Report and Written Opinion for corresponding International Application No. PCT/US08/07701, mailed Dec. 18, 2008 (9 pages). cited by other Adler et al. “A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)” The Journal of Infectious Diseases 180:843-846 (1999). cited by other Armas et al. “DNA Immunization Confers Protection Against Murine Cytomegalovirus Infection” Journal of Virology 70(11):7921-7928 (1996). cited by other Balasuriya et al. “Alphavirus Replicon Particles Expressing the Two Major Envelope Proteins of Equine Arteritis Virus Induce High Level Protection Against Challenge with Virulent Virus in Vaccinated Horses” Vaccine 20:1609-1617 (2002). cited by other Baric et al. “Expression and Self-Assembly of Norwalk Virus Capsid Protein from Venezuelan Equine Encephalitis Virus Replicons” Journal of Virology 76(6):3023-3030 (2002). cited by other Barouch et al. “Augmentation of Immune Responses to HIV-1 and Simian Immunodeficiency Virus DNA Vaccines by IL-2/Ig Plasmid Administration in Rhesus Monkeys” PNAS 97(8):4192-4197 (2000). cited by other Barry et al. “Expression Library Immunization to Discover and Improve Vaccine Antigens” Immunological Reviews 199:68-83 (2004). cited by other Bell et al. “Effect of Low-NaCl Medium on the Envelope Glycoproteins of Sindbis Virus” Journal of Virology 25(3):764-769 (1978). cited by other Berencsi et al. “A Canarypox Vector-Expressing Cytomegalovirus (CMV) Phosphoprotein 65 Induces Long-Lasting Cytotoxic T Cell Responses in Human CMV-Seronegative Subjects” The Journal of Infectious Diseases 183:1171-1179 (2001). cited by other Berencsi et al. “Murine Cytotoxic T Cell Response Specific for Human Cytomegalovirus Glycoprotein B (gB) Induced by Adenovirus and Vaccinia Recombinants Expressing gB” Journal of General Virology 74:2507-2512 (1993). cited by other Berglund et al. “Semliki Forest Virus Expression System: Production of Conditionally Infectious Recombinant Particles” Bio/Technology 11:916-920 (1993). cited by other Bergman et al. “Long-Term Survival of Dogs with Advanced Malignant Melanoma After DNA Vaccination with Xenogeneic Human Tyrosinase: A Phase I Trial” Clinical Cancer Research 9:1284-1290 (2003). cited by other Bernard et al. “Mutations in the E2 Glycoprotein of Venezuelan Equine Encephalitis Virus Confer Heparan Sulfate Interaction, Low Morbidity, and Rapid Clearance from Blood in Mice” Virology 276:93-103 (2000). cited by other Bernstein et al. “Randomized, Double-Blind, Phase 1 Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus in CMV Seronegative Adult Volunteers” Vaccine 28:484-493 (2010). cited by other Betts et al. “Cross-Clade Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Responses in HIV-Infected Zambians” J Virol 71(11):8908-8911 (1997). cited by other Bourne et al. “Preconception Immunization with a Cytomegalovirus (CMV) Glycoprotein Vaccine Improves Pregnancy Outcome in a Guinea Pig Model of Congenital CMV Infection” The Journal of Infectious Diseases 183:59-64 (2001). cited by other Bredenbeek et al. “Sindbis Virus Expression Vectors: Packaging of RNA Replicons by Using Defective Helper RNAs” Journal of Virology 67(11):6439-6446 (1993). cited by other Britt et al. “Formulation of an Immunogenic Human Cytomegalovirus Vaccine: Responses in Mice” The Journal of Infectious Diseases 171:18-25 (1995). cited by other Caley et al. “Humoral, Mucosal, and Cellular Immunity in Response to a Human Immunodeficiency Virus Type 1 Immunogen Expressed by a Venezuelan Equine Encephalitis Virus Vaccine Vector” J Virol 71(4):3031-3038 (1997). cited by other Caley et al. “Venezuelan Equine Encephalitis Virus Vectors Expressing HIV-1 Proteins: Vector Design Strategies for Improved Vaccine Efficacy” Vaccine 17:3124-3135 (1999). cited by other Caltenco-Serrano et al. “Cytomegalovirus Infection in Patients with Solid-Organ Transplant” Revista Latinameriana de Microbiologia 43(4):177-182 (2001). cited by other Carlson et al. “Expression, Purification and Characterization of a Soluble Form of Human Cytomegalovirus Glycoprotein B” Virology 239:198-205 (1997). cited by other Casimiro et al. “Vaccine-Induced Immune Responses in Rodents and Nonhuman Primates by Use of a Humanized Human Immunodeficiency Virus Type 1 pol Gene” Journal of Virology 76(1):185-194 (2002). cited by other Cassetti et al. “Antitumor Efficacy of Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Mutated HPV16 E6 and E7 Genes” Vaccine 22:520-527 (2004). cited by other Chappell et al. “A 9-nt Segment of a Cellular mRNA can Function as an Internal Ribosome Entry Site (IRES) and When Present in Linked Multiple Copies Greatly Enhances IRES Activity” PNAS 97(4):1536-1541 (2000). cited by other Chatterjee et al. “Modification of Maternal and Congenital Cytomegalovirus Infection by Anti-Glycoprotein B Antibody Transfer in Guinea Pigs” The Journal of Infectious Diseases 183:1547-1553 (2001). cited by other Corsini et al. “Efficiency of Transduction by Recombinant Sindbis Replicon Virus Varies Among Cell Lines, Including Mosquito Cells and Rat Sensory Neurons” BioTechniques 21:492-497 (1996). cited by other Cutler and Garoff. “Mutants of the Membrane-Binding Region of Semliki Forest Virus E2 Protein. I. Cell Surface Transport and Fusogenic Activity” The Journal of Cell Biology 102:889-901 (1986). cited by other Davis et al. “Alphavirus Replicon Particles as Candidate HIV Vaccines” IUBMB Life 53:209-211 (2002). cited by other Davis et al. “Attenuated Mutants of Venezuelan Equine Encephalitis Virus Containing Lethal Mutations in the PE2 Cleavage Signal Combined with a Second-Site Suppressor Mutation in E1” Virology 212:102-110 (1995). cited by other Davis et al. “Attenuating Mutations in the E2 Glycoprotein Gene of Venezuelan Equine Encephalitis Virus: Construction of Single and Multiple Mutants in a Full-Length cDNA Clone” Virology 183:20-31 (1991). cited by other Davis et al. “A Genetically Engineered Live Virus Vaccine for Venezuelan Equine Encephalitis” J Cell Biochemistry Supplement O, No. 17, Part D, Abstract N404 (1993). cited by other Davis et al. “Immunization Against Influenza with Attenuated Venezuelan Equine Encephalitis Virus Vectors” in Options for the Control of Influenza III., L.E. Brown, A.W. Hampson and R.G. Webster, eds. Elsevier, Amsterdam, pp. 803-809 (1996). cited by other Davis et al. “In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant” Virology 171:189-204 (1989). cited by other Davis et al. “In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant and Mutations Affecting Virulence” Vaccines 90:109-113 (1990). cited by other Davis et al. “A Molecular Genetic Approach to the Study of Venezuelan Equine Encephalitis Virus Pathogenesis” Archives of Virology 9:99-109 (1994). cited by other Davis et al. “A Single Nucleotide Change in the E2 Glycoprotein Gene of Sindbis Virus Affects Penetration Rate in Cell Culture and Virulence in Neonatal Mice” PNAS USA 83:6771-6775 (1986). cited by other Davis et al. “A Viral Vaccine Vector That Expresses Foreign Genes in Lymph Nodes and Protects Against Mucosal Challenge” Journal of Virology 70(6):3781-3787 (1996). cited by other Davis et al. “Vaccination of Macaques Against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles” J Virol 74(1):371-378 (2000). cited by other Deming et al. “Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants” PLoS Medicine 3(12)/e525:2359-2375 (2006). cited by other Dubensky et al. “Sindbis Virus DNA-Based Expression Vectors: Utility for in Vitro and in Vivo Gene Transfer” Journal of Virology 70(1):508-519 (1996). cited by other Dubuisson and Rice. “Sindbis Virus Attachment: Isolation and Characterization of Mutants with Impaired Binding to Vertebrate Cells” Journal of Virology 67(6):3363-3374 (1993). cited by other Durso et al. “A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses” Clin Cancer Res 13(13):3999-4008 (2007). cited by other Eiben et al. “Establishment of an HLA-A*0201 Human Papillomavirus Type 16 Tumor Model to Determine the Efficacy of Vaccination Strategies in HLA-A*0201 Transgenic Mice” Cancer Research 62:5792-5799 (2002). cited by other Elkington et al. “Ex Vivo Profiling of CD8=-T-Cell Responses to Human Cytomegalovirus Reveals Broad and Multispecific Reactivities in Healthy Virus Carriers” Journal of Virology 77(9):5226-5240 (2003). cited by other Elliott et al. “Alphavirus Replicon Particles Encoding the Fusion or Attachment Glycoproteins of Respiratory Syncytial Virus Elicit Protective Immune Responses in BALB/c Mice and Functional Serum Antibodies in Rhesus Macaques” Vaccine 25:7132-7144 (2007). cited by other Endresz et al. “Induction of Human Cytomegalovirus (HCMV)-Glycoprotein B (gB)-Specific Neutralizing Antibody and Phosphoprotein 65 (pp65)-Specific Cytotoxic T Lymphocyte Responses by Naked DNA Immunization” Vaccine 17:50-58 (1999). cited by other Erdman et al. “Alphavirus Replicon Particle Vaccines Developed for Use in Humans Induce High Levels of Antibodies to Influenza Virus Hemagglutinin in Swine: Proof of Concept” Vaccine 28:594-596 (2010). cited by other Erlap et al. “Doxorubicin and Paclitaxel Enhance the Antitumor Efficacy of Vaccines Directed Against HER 2/neu in a Murine Mammary Carcinoma Model” Breast Cancer Research 6:R275-R283 (2004). cited by other Favre et al. “Semliki Forest Virus Capsid Protein Expressed by a Baculovirus Recombinant” Archives of Virology 132:307-319 (1993). cited by other Feyzi et al. “Structural Requirement of Heparan Sulfate for Interaction with Herpes Simplex Viurs Type 1 Virions and Isolated Glycoprotein C*” The Journal of Biological Chemistry 272(40):24850-24857 (1997). cited by other Frey et al. “Effects of Antigen Dose and Immunization Regimens on Antibody Responses to a Cytomegalovirus Glycoprotein B Subunit Vaccine” The Journal of Infectious Diseases 180:1700-1703 (1999). cited by other Frolov et al. “Alphavirus-Based Expression Vectors: Strategies and Applications” PNAS USA 93:11371-11377 (1996). cited by other Garcia-Hernandez et al. “In vivo Effects of Vaccination with Six-Transmembrane Epithelial Antigen of the Prostate: A Candidate Antigen for Treating Prostate Cancer” Cancer Res 67(3):1344-1351 (2007). cited by other Garoff et al. “Expression of Semliki Forest Virus Proteins from Cloned Complementary DNA. II. The Membrane-Spanning Glycoprotein E2 is Transported to the Cell Surface Without its Normal Cytoplasmic Domain” The Journal of Cell Biology 97:652-658 (1983). cited by other Geigenmüller-Gnirke et al. “Complementation Between Sindbis Viral RNAs Produces Infectious Particles with a Bipartite Genome” PNAS USA 88:3253-3257 (1991). cited by other Geisbert et al. “Evaluation in Nonhuman Primates of Vaccines Against Ebola Virus” Emerging Infectious Diseases 8(5):503-507 (2002). cited by other Geysen et al. “A Priori Delineation of a Peptide which Mimics a Discontinuous Antigenic Determinant” Molecular Immunology 23(7):709-715 (1986). cited by other Geysen et al. “Use of a Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid” PNAS USA 81(13):3998-4002 (1984). cited by other Gidwitz et al. “Differences in Virion Stability Among Sindbis Virus Pathogenesis Mutants*” Virus Research 10:225-240 (1988). cited by other Gingras et al. “Activation of the Translational Suppressor 4E-BP1 Following Infection with Encephalomyocarditis Virus and Poliovirus” PNAS USA 93:5578-5583 (1996). cited by other Goldberg et al. “Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles” Clin Cancer Res 11(22):8114-8121 (2005). cited by other Golzio et al. “Cell Synchronization Effect on Mammalian Cell Permeabilization and Gene Delivery by Electric Field” Biochimica et Biophysica Acta 1563:23-28 (2002). cited by other Gönczöl and Plotkin. “Development of a Cytomegalovirus Vaccine: Lessons from Recent Clinical Trials” Exp Opin Biol Ther 1(3):401-412 (2001). cited by other Gönczöl et al. “Preclinical Evaluation of an ALVAC (Canarypox)-Human Cytomegalovirus Glycoprotein B Vaccine Candidate” Vaccine 13(12):1080-1085 (1995). cited by other Gradi et al. “Proteolysis of Human Eukaryotic Translation Initiation Factor eIF4GII, but Not eIF4GI, Coincides with the Shutoff of Host Protein Synthesis After Poliovirus Infection” PNAS USA 95:11089-11094 (1998). cited by other Grieder et al. “Specific Restrictions in the Progression of Venezuelan Equine Encephalitis Virus-Induced Disease Resulting from Single Amino Acid Changes in the Glycoproteins” Virology 206:994-1006 (1995). cited by other Gyulai et al. “Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1- Specific CTLs” The Journal of Infectious Diseases 181:1537-1546 (2000). cited by other Hahn et al. “Infectious Sindbis Virus Transient Expression Vectors for Studying Antigen Processing and Presentation” PNAS USA 89:2679-2683 (1992). cited by other Hariharan et al. “DNA Immunization Against Herpes Simplex Virus: Enhanced Efficacy Using a Sindbis Virus-Based Vector” Journal of Virology 72(2):950-958 (1998). cited by other Heidner et al. “Lethality of PE2 Incorporation into Sindbis Virus can be Suppressed by Second-Site Mutations in E3 and E2” Journal of Virology 68(4):2683-2692 (1994). cited by other Heise et al. “An Attenuating Mutation in nsP1 of the Sindbis-Group Virus S.A.AR86 Accelerates Nonstructural Protein Processing and Up-Regulates Viral 26S RNA Synthesis” Journal of Virology 77(2):1149-1156 (2003). cited by other Heiser et al. “Autologous Dendritic Cells Transfected with Prostate-Specific Antigen RNA Stimulate CTL Responses Against Metastatic Prostate Tumors” The Journal of Clinical Investigation 109(3):409-417 (2002). cited by other Herweijer and Wolff. “Self-Amplifying Vectors for Gene Delivery” Advanced Drug Delivery Reviews 27:5-16 (1997). cited by other Hevey et al. “Marburg Virus Vaccines Based Upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates” Virology 251:28-37 (1998). cited by other Hevey et al. “Marburg Virus Vaccines: Comparing Classical and New Approaches” Vaccine 20:586-593 (2002). cited by other Hill et al. “RNA-RNA Recombination in Sindbis Virus: Roles of the 3′ Conserved Motif, Poly(A) Tail, and Nonviral Sequences of Template RNAs in Polymerase Recognition and Template Switching” Journal of Virology 71(4):2693-2704 (1997). cited by other Hirsch et al. “Patterns of Viral Replication Correlate with Outcome in Simian Immunodeficiency Virus (SIV)-Infected Macaques: Effect of Prior Immunization with a Trivalent SIV Vaccine in Modified Vaccina Virus Ankara” J Virol 70(6):3741-3752 (1996). cited by other Hodgson et al. “Expression of Venezuelan Equine Encephalitis Virus Proteins by Recombinant Baculoviruses” The American Journal of Tropical Medicine and Hygiene 49:195-196 (Abstract) (1993). cited by other Holcik and Korneluk. “Functional Characterization of the X-Linked Inhibitor of Apoptosis (XIAP) Internal Ribosome Entry Site Element: Role of La Autoantigen in XIAP Translation” Molecular and Cellular Biology 20(13):4648-4657 (2000). cited by other Holcik et al. “A New Internal-Ribosome-Entry-Site Motif Potentiates XIAP-Mediated Cytoprotection” Nature Cell Biology 1:190-192 (1999). cited by other Holcik et al. “The Internal Ribosome Entry Site-Mediated Translation of Antiapoptotic Protein XIAP is Modulated by the Heterogeneous Nuclear Ribonucleoproteins C1 and C2” Molecular and Cellular Biology 23(1):280-288 (2003). cited by other Hooper et al. “Molecular Smallpox Vaccine Delivered by Alphavirus Replicons Elicits Protective Immunity in Mice and Non-Human Primates” Vaccine 28:494-511 (2010). cited by other Hubby et al. “Development and Preclinical Evaluation of an Alphavirus Replicon Vaccine for Influenza” Vaccine 25:8180-8189 (2007). cited by other International Search Report for International Application Serial No. PCT/US02/28610, mailed Feb. 11, 2003 (4 pages). cited by other International Search Report for International Application Serial No. PCT/US03/39723, mailed Aug. 17, 2004 (1 page). cited by other International Search Report for International Application Serial No. PCT/US03/39725, mailed Dec. 3, 2004 (3 pages). cited by other International Search Report for International Application Serial No. PCT/US04/008458, mailed Oct. 25, 2004 (10 pages). cited by other International Search Report for International Application Serial No. PCT/USO4/021772, mailed Dec. 28, 2004 (18 pages). cited by other Jalanko. “Expression of Semliki Forest Virus Capsid Protein from SV40 Recombinant Virus” FEBS Letters 186(1):59-64 (1985). cited by other Jang and Wimmer. “Cap-Independent Translation of Encephalomyocarditis Virus RNA: Structural Elements of the Internal Ribosomal Entry Site and Involvement of a Cellular 57-kD RNA-Binding Protein” Genes & Development 4:1560-1572 (1990). cited by other Jiang et al. “Sterile Protection Against Plasmodium knowlesi in Rhesus Monkeys from a Malaria Vaccine: Comparison of Heterologous Prime Boost Strategies” PLoS ONE 4(8)/e6559:1-12 (2009). cited by other Joachims et al. “Cleavage of Poly(A)-Binding Protein by Enterovirus Proteases Concurrent with Inhibition of Translation in Vitro” Journal of Virology 73(1):718-727 (1999). cited by other Johnston and Peters. “Alphaviruses” in Fields Virology, 3rd ed., Lippincott-Raven Publishers, Philadelphia, Chapter 28, pp. 843-898 (1996). cited by other Johnston and Smith. “Selection for Accelerated Penetration in Cell Culture Coselects for Attenuated Mutants of Venezuelan Equine Encephalitis Virus1” Virology 162:437-443 (1988). cited by other Johnston et al. “Studies of Alphavirus Virulence Using Full-Length Clones of Sindbis and Venezuelan Equine Encephalitis Viruses” in New Aspects of Positive Strand RNA Viruses, M.A. Brinton et al. (eds.), ASM Press, Chapter 49, pp. 334-339 (1990). cited by other Johnston et al. “Vaccination of Macaques with Siv Immunogens Delivered by Venezuelan Equine Encephalitis Virus Replicon Particle Vectors Followed by a Mucosal Challenge with SIVsmE660” Vaccine 23:4969-4979 (2005). cited by other Kamrud et al. “Analysis of Venezuelan Equine Encephalitis Replicon Particles Packaged in Different Coats” PLoS ONE 3(7)/e2709:1-8 (2008). cited by other Kaufman et al. “Improved Vectors for Stable Expression of Foreign Genes in Mammalian Cells by use of the Untranslated Leader Sequence from EMC Virus” Nucleic Acids Research 19(16):4485-4490 (1991). cited by other Kern et al. “Cytomegalovirus (CMV) Phosphoprotein 65 Makes a Large Contribution to Shaping the T Cell Repertoire in CMV-Exposed Individuals” The Journal of Infectious Diseases 185:1709-1716 (2002). cited by other Khromykh. “Replicon-Based Vectors of Positive Strand RNA Viruses” Current Opinion in Molecular Therapeutics 2(5):555-569 (2000). cited by other Kinney et al. “Attenuation of Venezuelan Equine Encephalitis Virus Strain TC-83 is Encoded by the 5′-Noncoding Region and the E2 Envelope Glycoprotein” Journal of Virology 67(3):1269-1277 (1993). cited by other Kinney et al. “The Full-Length Nucleotide Sequences of the Virulent Trinidad Donkey Strain of Venezuelan Equine Encephalitis Virus and its Attenuated Vaccine Derivative, Strain TC-83” Virology 170:19-30 (1989). cited by other Klimstra et al. “Adaptation of Sindbis Virus to BHK Cells Selects for Use of Heparan Sulfate as an Attachment Receptor” Journal of Virology 72(9):7357-7366 (1998). cited by other Knight. “Secretion from Bovine Chromaffin Cells Acutely Expressing Exogenous Proteins Using a Recombinant Semliki Forest Virus Containing an EGFP Reporter” Molecular and Cellular Neuroscience 14:486-505 (1999). cited by other Koh et al. “Androgen Ablation Augments Prostate Cancer Vaccine Immunogenicity Only When Applied After Immunization” The Prostate 69:571-584 (2009). cited by other Kohl et al. “Transient Gene Expression in Mammalian and Mosquito Cells Using a Recombinant Semliki Forest Virus Expressing T7 RNA Polymerase” Applied Microbiology and Biotechnology 53:51-56 (1999). cited by other Koller et al. “A High-Throughput Alphavirus-Based Expression Cloning System for Mammalian Cells” Nature Biotech 19:851-855 (2001). cited by other Kondor-Koch et al. “Expression of Semliki Forest Virus Proteins from Cloned Complementary DNA. I. The Fusion Activity of the Spike Glycoprotein” The Journal of Cell Biology 97:644-651 (1983). cited by other Kowalski et al. “Evaluation of Neurovirulence and Biodistribution of Venezuelan Equine Encephalitis Replicon Particles Expressing Herpes Simplex Virus Type 2 Glycoprotein D” Vaccine 25:2296-2305 (2007). cited by other Kumamoto et al. “Induction of Tumor-Specific Protective Immunity by in situ Langerhans Cell Vaccine” Nature Biotechnology 20:64-69 (2002). cited by other Laust et al. “VRP Immunotherapy Targeting neu: Treatment Efficacy and Evidence for Immunoediting in a Stringent Rat Mammary Tumor Model” Breast Cancer Res Treat 106:371-382 (2007). cited by other Lee et al. “Candidate Vaccine Against Botulinum Neurotoxin Serotype A Derived from a Venezuelan Equine Encephalitis Virus Vector System” Infection and Immunity 69(9):5709-5715 (2001). cited by other Lee et al. “Efficient Long-Term Coexpression of a Hammerhead Ribozyme Targeted to the U5 Region of HIV-1 LTR by Linkage to the Multidrug-Resistance Gene” Antisense & Nucleic Acid Drug Development 7:511-522 (1997). cited by other Lee et al. “Immune Protection Against Staphylococcal Enterotoxin-Induced Toxic Shock by Vaccination with a Venezuelan Equine Encephalitis Virus Replicon” The Journal of Infectious Diseases 185:1192-1196 (2002). cited by other Lee et al. “Multiagent Vaccines Vectored by Venezuelan Equine Encephalitis Virus Replicon Elicits Immune Responses to Marburg Virus and Protection Against Anthrax and Botulinum Neurotoxin in Mice” Vaccine 24:6886-6892 (2006). cited by other Leitner et al. “Enhancement of Tumor-Specific Immune Response with Plasmid DNA Replicon Vectors” Cancer Research 60:51-55 (2000). cited by other Lemm and Rice. “Assembly of Functional Sindbis Virus RNA Replication Complexes: Requirement for Coexpression of P123 and P34” Journal of Virology 67(4):1905-1915 (1993). cited by other Lemm et al. “Polypeptide Requirements for Assembly of Functional Sindbis Virus Replication Complexes: a Model for the Temporal Regulation of Minus- and Plus-Strand RNA Synthesis” The EMBO Journal 13(12):2925-2934 (1994). cited by other Leone et al. “In Vitro Synthesis of the Gene Coding for the Glycoprotein E1 of Sindbis Virus” Microbiologica 8(2):123-130 (1985) (Abstract Only). cited by other Li and Garoff. “Production of Infectious Recombinant Moloney Murine Leukemia Virus Particles in BHK Cells Using Semliki Forest Virus-Derived RNA Expression Vectors” PNAS USA 93:11658-11663 (1996). cited by other Liljeström. “Alphavirus Expression Systems” Current Opinion in Biotechnology 5:495-500 (1994). cited by other Liljeström and Garoff. “A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon” Bio/Technology 9:1356-1361 (1991). cited by other Liljeström et al. “In Vitro Mutagenesis of a Full-Length cDNA Clone of Semliki Forest Virus: The Small 6,000-Molecular-Weight Membrane Protein Modulates Virus Release” Journal of Virology 65(8):4107-4113 (1991). cited by other Lobigs and Garoff. “Fusion Function of the Semliki Forest Virus Spike is Activated by Proteolytic Cleavage of the Envelope Glycoprotein Precursor p62” Journal of Virology 64(3):1233-1240 (1990). cited by other LoBUE et al. “Multivalent Norovirus Vaccines Induce Strong Mucosal and Systemic Blocking Antibodies Against Multiple Strains” Vaccine 24:5220-5234 (2006). cited by other Lu and Silver. “Transmission of Replication-Defective Sindbis Helper Vectors Encoding Capsid and Envelope Proteins” Journal of Virological Methods 91:59-65 (2001). cited by other Lundström. “Alphavirus Vectors: Applications for DNA Vaccine Production and Gene Expression” Intervirology 43:247-257 (2000). cited by other Lundström et al. “Secretion of Semliki Forest Virus Membrane Glycoprotein E1 From Bacillus subtilis” Virus Research 2:69-83 (1985). cited by other MacDonald and Johnston. “Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathogenesis” Journal of Virology 74(2):914-922 (2000). cited by other MacLachlan et al. “Experiences with New Generation Vaccines Against Equine Viral Arteritis, West Nile Disease and African Horse Sickness” Vaccine 25:5577-5582 (2007). cited by other Maecker et al. “Use of Overlapping Peptide Mixtures as Antigens for Cytokine Flow Cytometry” Journal of Immunological Methods 255:27-40 (2001). cited by other Marshall et al. “An Adenovirus Recombinant that Expresses the Human Cytomegalovirus Major Envelope Glycoprotein and Induces Neutralizing Antibodies” The Journal of Infectious Diseases 162:1177-1181 (1990). cited by other Martinez-Salas et al. “Functional Interactions in Internal Translation Initiation Directed by Viral and Cellular IRES Elements” Journal of General Virology 82:973-984 (2001). cited by other McCue and Anders. “Soluble Expression and Complex Formation of Proteins Required for HCMV DNA Replication Using the SFV Expression System” Protein Expression and Purification 13:301-312 (1998). cited by other McKnight et al. “Deducted Consensus Sequence of Sindbis Virus Strain AR339: Mutations Contained in Laboratory Strains Which Affect Cell Culture and in Vivo Phenotypes” Journal of Virology 70(3):1981-1989 (1996). cited by other Melancon and Garoff. “Processing of the Semliki Forest Virus Structural Polyprotein: Role of the Capsid Protease” Journal of Virology 61(5):1301-1309 (1987). cited by other Melancon and Garoff. “Reinitiation of Translocation in the Semliki Forest Virus Structural Polyprotein: Identification of the Signal for the E1 Glycoprotein” The EMBO Journal 5(7):1551-1560 (1986). cited by other Mok et al. “Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Respiratory Syncytial Virus Surface Glycoproteins Induce Protective Mucosal Responses in Mice and Cotton Rats” Journal of Virology 81(24):13710-13722 (2007). cited by other Moran et al. “Alphaviral Vector-Transduced Dendritic Cells are Successful Therapeutic Vaccines Against neu-Overexpressing Tumors in Wild-Type Mice” Vaccine 25:6604-6612 (2007). cited by other Morello et al. “Suppression of Murine Cytomegalovirus (MCMV) Replication with a DNA Vaccine Encoding MCMV M84 (a Homolog of Human Cytomegalovirus pp65)” Journal of Virology 74(8):3696-3708 (2000). cited by other Morenstern and Land. “Advanced Mammalian Gene Transfer: High Titre Retroviral Vectors with Multiple Drug Selection Markers and a Complementary Helper-Free Packaging Cell Line” Nucleic Acids Research 18(12):3587-3596 (1990). cited by other Nelson et al. “Venezuelan Equine Encephalitis Replicon Immunization Overcomes Intrinsic Tolerance and Elicits Effective Anti-Tumor Immunity to the ‘Self’ Tumor-Associated Antigen, neu in a Rat Mammary Tumor Model” Breast Cancer Research and Treatment 82:169-183 (2003). cited by other Nishimoto et al. “Restricted and Selective Tropism of Venezuelan Equine Encephalitis Virus-Derived Replicon Vector for Human Dendritic Cells” Viral Immunology 20(1):88-104 (2007). cited by other Oker-Blom and Summers. “Expression of Sindbis Virus 26S cDNA in Spodoptera frugiperda (Sf9) Cells, Using a Baculovirus Expression Vector” Journal of Virology 63(3):1256-1264 (1989). cited by other Olmsted et al. “Characterization of Sindbis Virus Epitopes Important for Penetration in Cell Culture and Pathogenesis in Animals1” Virology 148:245-254 (1986). cited by other Olmsted et al. “Sindbis Virus Mutants Selected for Rapid Growth in Cell Culture Display Attenuated Virulence in Animals” Science 225(4660):424-427 (1984). cited by other Orkin and Motulsky. “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy” (42 pages)(1995). cited by other Overwijk and Restifo. “Creating Therapeutic Cancer Vaccines: Notes from the Battlefield” Trends in Immunology 22(1):5-7 (2001). cited by other Pardoll. “Cancer Vaccines” Nature Medicine Vaccine Supplement 4(5):525-531 (1998). cited by other Pardoll. “Spinning Molecular Immunology into Successful Immunotherapy” Nature Reviews—Immunology 2:227-238 (2002). cited by other Paredes et al. “Three-Dimensional Structure of a Membrane-Containing Virus” PNAS USA 90:9095-9099 (1993). cited by other Pass and Burke. “Development of Cytomegalovirus Vaccines: Prospects for Prevention of Congenital CMV Infection” Seminars in Pediatric Infectious Diseases 13(3):196-204 (2002). cited by other Pass et al. “A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B and a New Adjuvant” The Journal of Infectious Diseases 180:970-975 (1999). cited by other Pedersen and Eddy. “Separation, Isolation, and Immunological Studies of the Structural Proteins of Venezuelan Equine Encephalomyelitis Virus” J Virology 14(4):740-744 (1974). cited by other Plotkin et al. “Multicenter Trial of Towne Strain Attenuated Virus Vaccine in Seronegative Renal Transplant Recipients” Transplantation 58(11):1176-1178 (1994). cited by other Polo and Johnston. “Attenuating Mutations in Glycoproteins E1 and E2 of Sindbis Virus Produce a Highly Attenuated Stain when Combined in Vitro” Journal of Virology 64(9):4438-4444 (1990). cited by other Polo and Johnston. “A Model for in Vitro Development of Live, Recombinant Alphavirus Vaccines” in Vaccines 90: Modern Approaches to New Vaccines Including Prevention of AIDS, Brown et al. (eds), Cold Spring Harbor Laboratory, pp. 105-108 (1990). cited by other Polo and Johnston. “Mutational Analysis of Virulence Locus in the E2 Glycoprotein Gene of Sindbis Virus” Journal of Virology 65(11):6358-6361 (1991). cited by other Polo et al. “Stable Alphavirus Packaging Cell Lines for Sindbis Virus- and Semliki Forest Virus-Derived Vectors” PNAS USA 96:4598-4603 (1999). cited by other Presley et al. “Proteolytic Processing of the Sindbis Virus Membrane Protein Precursor PE2 is Nonessential for Grown in Vertebrate Cells but is Required for Efficient Growth in Invertebrate Cells” Journal of Virology 65(4):1905-1909 (1991). cited by other Pugachev et al. “Development of a Rubella Virus Vaccine Expression Vector: Use of a Picornavirus Internal Ribosome Entry Site Increases Stability of Expression” Journal of Virology 74(22):10811-10815 (2000). cited by other Pugachev et al. “Double-Subgenomic Sindbis Virus Recombinants Expressing Immunogenic Proteins of Japanese Encephalitis Virus Induce Significant Protection in Mice Against Lethal JEV Infection” Virology 212:587-594 (1995). cited by other Pushko et al. “Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs Against Infection with Lassa and Ebola Viruses” Journal of Virology 75(23):11677-11685 (2001). cited by other Pushko et al. “Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization Against Heterologous Pathogens in Vivo” Virology 239:389-401 (1997). cited by other Ragupathi and Livingston. “The Case for Polyvalent Cancer Vaccines that Induce Antibodies” Expert Rev Vaccines 1(2):193-206 (2002). cited by other Rayner et al. “Alphavirus Vectors and Vaccinations” Reviews in Medical Virology 12:279-296 (2002). cited by other Reap et al. “Cellular and Humoral Immune Responses to Alphavirus Replicon Vaccines Expressing Cytomegalovirus pp65, IE1, and gB Proteins” Clinical and Vaccine Immunology 14(6):748-755 (2007). cited by other Reap et al. “Development and Preclinical Evaluation of an Alphavirus Replicon Particle Vaccine for Cytomegalovirus” Vaccine 25:7441-7449 (2007). cited by other Rice et al. “Expression of Sindbis Virus Structural Proteins via Recombinant Vaccinia Virus: Synthesis, Processing, and Incorporation into Mature Sindbis Virions” J Virology 56(1):227-239 (1985). cited by other Riedel. “Different Membrane Anchors Allow the Semliki Forest Virus Spike Subunit E2 to Reach the Cell Surface” Journal of Virology 54:224-228 (1985). cited by other Roberts and Belsham. “Complementation of Defective Picornavirus Internal Ribosome Entry Site (IRES) Elements by the Coexpression of Fragments of the IRES” Virology 227:53-62 (1997). cited by other Russell et al. “Sindbis Virus Mutations Which Coordinately Affect Glycoprotein Processing, Penetration, and Virulence in Mice” Journal of Virology 63(4):1619-1629 (1989). cited by other Sadanaga et al. “Dendritic Cell Vaccination with MAGE Peptide is a Novel Therapeutic Approach for Gastrointestinal Carcinomas1” Clinical Cancer Research 7:2277-2284 (2001). cited by other Salminen et al. “Membrane Fusion Process of Semliki Forest Virus II: Cleavage-Dependent Reorganization of the Spike Protein Complex Controls Virus Entry” The Journal of Cell Biology 116(2):349-357 (1992). cited by other Schleiss. “Animal Models of Congenital Cytomegalovirus Infection: An Overview of Progress in the Characterization of Guinea Pig Cytomegalovirus (GPCMV)” Journal of Clinical Virology 25:S37-S49 (2002). cited by other Schleiss et al. “Preconceptual Administration of an Alphavirus Replicon UL83 (pp65 Homolog) Vaccine Induces Humoral and Cellular Immunity and Improves Pregnancy Outome in the Guinea Pig Model of Congenital Cytomegalovirus Infection” The Journal of Infectious Diseases 195:789-798 (2007). cited by other Schlesinger. “Alphaviruses—Vectors for the Expression of Heterologous Genes” TiBTech 11:18-22 (1993). cited by other Schlesinger and Dubensky. “Alphavirus Vectors for Gene Expression and Vaccines” Current Opinion in Biotechnology 10:434-439 (1999). cited by other Schlesinger and Schlesinger. “Togaviridae: The Viruses and Their Replication” in Fields Virology, 3rd ed. (Fields et al., eds.), Lipincott-Raven Publishers, Philadelphia, Chapter 27, pp. 825-841 (1996). cited by other Schoepp and Johnston. “Directed Mutagenesis of a Sindbis Virus Pathogenesis Site” Virology 193:149-159 (1993). cited by other Schultz-Cherry et al. “Influenza Virus (A/HK/156/97) Hemagglutinin Expressed by an Alphavirus Replicon System Protects Chickens Against Lethal Infection with Hong Kong-Origin H5N1 Viruses” Virology 278:55-59 (2000). cited by other Shi et al. “Construction and Characterization of Subgenomic Replicons of New York Strain of West Nile Virus” Virology 296:219-233 (2002). cited by other Simpson et al. “Complete Nucleotide Sequence and Full-Length cDNA Clone of S.A.AR86, a South African Alphavirus Related to Sindbis1” Virology 222:464-469 (1996). cited by other Sjöberg et al. “A Significantly Improved Semliki Forest Virus Expression System Based on Translation Enhancer Segments from the Viral Capsid Gene” Bio/Technology 12:1127-1131 (1994). cited by other Slepushkin et al. “Large-Scale Purification of a Lentiviral Vector by Size Exclusion Chromatography or Mustang Q Ion Exchange Capsule” BioProcessing Journal, Sep./Oct., pp. 89-95 (2003). cited by other Smerdou and Liljeström. “Two-Helper RNA System for Production of Recombinant Semliki Forest Virus Particle” Journal of Virology 73(2):1092-1098 (1999). cited by other Speckner et al. “Antigenic Domain 1 of Human Cytomegalovirus Glycoprotein B Induces a Multitude of Different Antibodies Which, when Combined, Results in Incomplete Virus Neutralization” Journal of General Virology 80:2183-2191 (1999). cited by other Strauss and Strauss. “Alphavirus Proteinases” Seminars in Virology 1:347-356 (1990). cited by other Strauss and Strauss. “The Alphaviruses: Gene Expression, Replication, and Evolution” Microbiological Reviews 58(3):491-562 (1994). cited by other Suomalainen et al. “Spike Protein-Nucleocapsid Interactions Drive the Budding of Alphaviruses” Journal of Virology 66(8):4737-4747 (1992). cited by other Sykes and Johnston. “Genetic Live Vaccines Mimic the Antigenicity but not Pathogenicity of Live Viruses” DNA and Cell Biology 18(7):521-531 (1999). cited by other Sylte et al. “Influenza Neuraminidase Antibodies Provide Partial Protection for Chickens Against High Pathogenic Avian Influenza Infection” Vaccine 25:3763-3772 (2007). cited by other Technical Bulletin No. 166: “RiboMAX™ Large Scale RNA Production Systems—SP6 and T7” Promega Corporation, pp. 1-11 (Revised Sep. 2001; http://www.promega.com/tbs/tb166.pdf on Nov. 4, 2004). cited by other Temperton. “DNA Vaccines Against Cytomegalovirus: Current Progress” International Journal of Antimicrobial Agents 19:169-172 (2002). cited by other Thompson and Sarnow. “Enterovirus 71 Contains a Type I IRES Element that Functions When Eukaryotic Initiation Factor eIF4G is Cleaved” Virology 315:259-266 (2003). cited by other Thompson et al. “Mucosal and Systemic Adjuvant Activity of Alphavirus Replicon Particles” PNAS USA 103(10):3722-3727 (2006). cited by other Thornburg et al. “Vaccination with Venezuelan Equine Encephalitis Replicons Encoding Cowpox Virus Structural Proteins Protects Mice From Intranasal Cowpox Virus Challenge” Virology 362:441-452 (2007). cited by other Tugizov et al. “Mutated Forms of Human Cytomegalovirus Glycoprotein B are Impaired in Inducing Syncytium Formation” Virology 209:580-591 (1995). cited by other Ubol et al. “Neurovirulent Strains of Alphavirus Induce Apoptosis in bcl-2-Expressing Cells: Role of a Single Amino Acid Change in the E2 Glycoprotein” PNAS USA 91:5202-5206 (1994). cited by other Van Der Velden et al. “Defective Point Mutations of the Encephalomyocarditis Virus Internal Ribosome Entry Site can be Complemented in Trans” Virology 214:82-90 (1995). cited by other Vander Veen et al. “Rapid Development of an Efficacious Swine Vaccine for Novel H1N1” PLoS Curr Influenza RRN1123 (10 pages) (2009). cited by other Vaz-Santiago et al. “Ex Vivo Stimulation and Expansion of Both CD4+and CD8+T Cells from Peripheral Blood Mononuclear Cells of Human Cytomegalovirus-Seropositive Blood Donors by Using a Soluble Recombinant Chimeric Protein, IE1-pp65” Journal of Virology 75(17):7840-7847 (2001). cited by other Velders et al. “Eradication of Established Tumors by Vaccination with Venezuelan Equine Encephalitis Virus Replicon Particles Delivering Human Papillomavirus 16 E7 RNA1” Cancer Research 61:7861-7867 (2001). cited by other Verma and Somia. “Gene Therapy—Promises, Problems and Prospects” Nature 389:239-242 (1997). cited by other Waite et al. “Inhibition of Sindbis Virus Production by Media of Low Ionic Strength: Intracellular Events and Requirements for Reversal” Journal of Virology 5:60-71 (1970). cited by other Walter et al. “Reconstitution of Cellular Immunity Against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer T-Cell Clones from the Donor” The New England Journal of Medicine 333:1038-1044 (1995). cited by other Wang et al. “Alphavirus Replicon Particles Containing the Gene for HER2/neu Inhibit Breast Cancer Growth and Tumorigenesis” Breast Cancer Research 7:R145-R155 (2005). cited by other Wang et al. “Core Protein-Coding Sequence, but not Core Protein, Modulates the Efficiency of Cap-Independent Translation Directed by the Internal Ribosome Entry Site of Hepatitis C Virus” Journal of Virology 74(23):11347-11358 (2000). cited by other Ward et al. “Immunotherapeutic Potential of Whole Tumour Cells” Cancer Immunol Immunother 51:351-357 (2002). cited by other Weiss and Schlesinger. “Recombination Between Sindbis Virus RNAs” Journal of Virology 65(8):4017-4025 (1991). cited by other Wen et al. “Expression of Genes Encoding Vesicular Stomatitis and Sindbis Virus Glycoproteins in Yeast Leads to Formation of Disulfide-Linked Oligomers” Virology 153 :150-154 (1986). cited by other Wen et al. “Tricistronic Viral Vectors Co-Expressing Interleukin-12 (1L-12) and CD80 (B7-1) for the Immunotherapy of Cancer: Preclinical Studies in Myeloma” Cancer Gene Therapy 8(5):361-370 (2001). cited by other White et al. “An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice” Journal of Virology 81(19):10329-10339 (2007). cited by other Williamson et al. “Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development” AIDS Research and Human Retroviruses 19(2):133-144 (2003). cited by other Williamson et al. “Designing HIV-1 Subtype C Vaccines for South Africa” South African Journal of Science 96:318-324 (2000). cited by other Wilson and Hart. “Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral Nucleoprotein” Journal of Virology 75(6):2660-2664 (2001). cited by other Wilson et al. “Naturally Occurring Dicistronic Cricket Paralysis Virus RNA is Regulated by Two Internal Ribosome Entry Sites” Molecular and Cellular Biology 20(14):4990-4999 (2000). cited by other Wilson et al. “Vaccine Potential of Ebola Virus VP24, VP30, VP35 and VP40 Proteins” Virology 286:384-390 (2001). cited by other Xiong et al. “Sindbis Virus: An Efficient, Broad Host Range Vector for Gene Expression in Animal Cells” Science 243:1188-1191 (1989). cited by other Yamanaka et al. “Enhancement of Antitumor Immune Response in Glioma Models in Mice by Genetically Modified Dendritic Cells Pulsed with Semliki Forest Virus-Mediated Complementary DNA” J Neurosurg 94:474-481 (2001). cited by other Yamanaka et al. “Marked Enhancement of Antitumor Immune Responses in Mouse Brain Tumor Models by Genetically Modified Dendritic Cells Producing Semliki Forest Virus-Mediated Interleukin-12” J Neurosurg 97:611-618 (2002). cited by other Yang and Sarnow. “Location of the Internal Ribosome Entry Site in the 5′ Non-Coding Region of the Immunoglobulin Heavy-Chain Binding Protein (BiP) mRNA: Evidence for Specific RNA-Protein Interactions” Nucleic Acids Research 25(14):2800-2807 (1997). cited by other Ying et al. “Cancer Therapy Using a Self-Replicating RNA Vaccine” Nature Medicine 5(7):823-827 (1999). cited by other Zhao and Garoff. “Role of Cell Surface Spikes in Alphavirus Budding” Journal of Virology 66(12):7089-7095 (1992). cited by other |
| Primary Examiner: | Mosher, Mary E |
| Attorney, Agent or Firm: | Myers Bigel Sibley & Sajovec |
| رقم الانضمام: | edspgr.07850977 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |